Curiox Biosystems 2026 Q1: Revenue Up 44%, Net Loss Narrows, Still Loss-Making
Consolidated Q1 2026 revenue KRW 1,325M (up ~44% YoY from KRW 922M), consolidated net loss KRW 2,641M (narrowed from KRW 3,617M in Q1 2025)
Expanding market with new product launches (Pluto LT/MT/HT) and Pluto Code software license model
Cash and cash equivalents at end-March 2026: KRW 10,058M (down from KRW 14,785M at year-end 2025); convertible bonds carrying amount KRW 1,943M (face value KRW 4,000M, conversion price KRW 21,350)
R&D expenses for the quarter: KRW 610M (down from KRW 734M in Q1 2025)
Contingent liabilities: one minor lawsuit (CNY 144,000); designated as unfaithful disclosure company due to delayed disclosure of derivative valuation loss (1 penalty point)
No shareholder return disclosures (no share buyback/cancellation or dividends)